Commercial Insight: Top 20 Cancer Therapy Brands - Sales of targeted therapies

Questions: Discounts, Updates etc.

Price: $15,200.00

Publication Date: 2007-07-03

Order Online Now

People that purchased this report also purchased:

Contact LeadDiscovery

  • If you have questions about this report
  • To find out if you qualify for a discount
  • Want a more up to date version
  • Can't find a report that meets your needs
Search all reports

Keywords:

Boolean terms AND, OR, NOT can be used. Phrases should be entered within quotes. For wildcards use an *

Sales of the Top 20 cancer therapy brands in each of the seven major markets totaled $24.5 billion in 2006 and are forecast to grow at a CAGR of 6.6% to $45.9 billion by 2016. Four newly marketed drugs are expected to become part of the Top 20 cancer therapy brands during the forecast period and are set to increase the 2016 sales of the existing Top 20 cancer therapy brands to $52.7 billion.


Scope

  • Overview of the current Top 20 cancer therapy brands market
  • Individual country, 5EU and seven-market sales forecasts from 2006 to 2016 for the leading cancer therapy brands
  • Segmentation and analysis of market dynamics by country sales, drug class, indication, company and impacted events
  • Detailed product profiles and discussion of assumptions and events used in forecast analysis


    • Report Highlights
    Four newly marketed drugs are expected to become part of the Top 20 cancer therapies during the forecast period: Sutent (sunitinib; Pfizer), Nexavar (sorafenib; Onyx/Bayer), Vectibix (panitumumab; Amgen) and Tykerb (lapatinib; GSK). These products combined with the existing Top 20 cancer therapies are set to reach $52.7 billion in sales by 2016.

    The Top 20 cancer therapy brands are forecast to experience 144 different events between 2007 and 2016. Considering the fact that many of these events will take place in each of the seven major markets, Datamonitor expects the Top 20 cancer therapy brands to experience 792 events across the 7MM.

    The 35 drugs that make up the Top 20 cancer therapy brands have gained approval in 18 different tumor types. Three of the 'big four' tumor types boast the highest number of leading cancer therapy brands namely: breast cancer with 18 of the 35 forecasted drugs, non-small cell lung cancer with eight, and colorectal cancer with seven.


    Reasons to Purchase

  • Understand market specific drivers and predict the future potential of key cancer therapy brands
  • Quantify the impact of key patent expiries and product launches and gain a valuable insight into the market dynamics
  • Consider, assess and react to opportunities and risks influencing the leading cancer therapy brands

    • Table of Contents

    Other users found this report page using the following search terms: targeted therapy kinase immunotherapy doxil avastin japan oncology market 2007 2006 tamoxifen sales innovative

    If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.